A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC

被引：0

作者：

Hayakawa, Daisuke ^{[1
]}

Takeda, Masayuki ^{[2
,3
]}

Shimokawa, Mototsugu ^{[4
]}

Nakamura, Atsushi ^{[5
]}

Nosaki, Kaname ^{[6
]}

Watanabe, Yasutaka ^{[7
]}

Kato, Terufumi ^{[8
]}

Tanaka, Hiroshi ^{[9
]}

Takahashi, Toshiaki ^{[10
]}

Oki, Masahide ^{[11
]}

Tachihara, Motoko ^{[12
]}

Fujimoto, Daichi ^{[13
]}

Yamaguchi, Kakuhiro ^{[14
]}

Hayashi, Hidetoshi ^{[2
]}

Yamamoto, Shoichiro ^{[15
]}

Iwama, Eiji ^{[16
]}

Azuma, Koichi ^{[17
]}

Yamamoto, Nobuyuki ^{[13
]}

Nakagawa, Kazuhiko ^{[2
]}

机构：

[1] Juntendo Univ, Dept Resp Med, Grad Sch Med, Tokyo, Japan

[2] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan

[3] Nara Med Univ, Dept Canc Genom & Med Oncol, Kashihara, Nara, Japan

[4] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Yamaguchi, Japan

[5] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[7] Saitama Canc Ctr, Div Thorac Oncol, Saitama, Japan

[8] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan

[9] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[10] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[11] Natl Hosp Org Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[12] Kobe Univ, Grad Sch, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan

[13] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[14] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[15] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephr, Ehime, Japan

[16] Kyushu Univ, Dept Resp Med, Grad Sch Med Sci, Fukuoka, Japan

[17] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan

[18] Japan Lung Canc Alliance, Yokohama, Kanagawa, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.128

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O7-2

引用

页码：S1387 / S1387

页数：1

共 50 条

[41] Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid
Theoleyre, Sandrine
Masson, Ingrid
Herbreteau, Guillaume
Vallee, Audrey
Senellart, Helene
Denis, Marc G.
LUNG CANCER, 2017, 114 : 111 - 112
[42] Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC
Santos, Edgardo
Kaplan, Barry
Kirshner, Eli
Croft, Elisabeth
Sequist, Lecia
Burke, Lea
Munley, Jiefen
Oxnard, Geoffrey
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1237 - S1237
[43] Phase II study of osimertinib in patients with plasma EGFR T790M positive advanced lung cancer (WJOG8815L/LPS)
Takahama, Takayuki
Azuma, Koichi
Shimokawa, Mototsugu
Kato, Terufumi
Daga, Haruko
Okamoto, Isamu
Akamatsu, Hiroaki
Takahashi, Toshiaki
Ohira, Tatsuo
Yokoyama, Toshihide
Hirano, Katsuya
Shiraishi, Yoshimasa
Himeji, Daisuke
Yamamoto, Nobuyuki
Nishio, Kazuto
Nakagawa, Kazuhiko
ANNALS OF ONCOLOGY, 2018, 29
[44] Mechanisms of acquired resistance to osimertinib in advanced NSCLC with EGFR T790M mutation (LOGIK1607)
Yamaguchi, Masafumi
Osoegawa, Atsushi
Nakamura, Tomomi
Morinaga, Ryotaro
Tanaka, Kentaro
Kashiwabara, Kosuke
Miura, Takashi
Suetsugu, Takayuki
Taguchi, Kenichi
Nabeshima, Kazuki
Kishimoto, Junji
Sakai, Kazuko
Nishio, Kazuto
Sugio, Kenji
CANCER SCIENCE, 2021, 112 : 567 - 567
[45] Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.
Lee, Ki Hyeong
Ahn, Myung-Ju
Han, Ji-Youn
Kim, Sang-We
Cho, Eun Kyung
Lee, Yun-Gyoo
Kim, Dong-Wan
Kim, Joo-Hang
Lee, Jong-Seok
Lee, Gyeong-Won
Shim, Byoung Yong
Kim, Jin-Soo
Chun, Sang Hoon
Lee, Sung Sook
Min, Young Joo
Shin, Sang Won
Hong, Min Hee
Sun, Jong-Mu
Byun, Hae Mi
Cho, Byoung Chul
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[46] An audit on the use of osimertinib in T790M EGFR+ patients at West Suffolk Hospital
Davis, O.
Patterson, D.
Martin, A.
LUNG CANCER, 2019, 127 : S40 - S40
[47] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
Zhang, Yidan
Xu, Yingqi
Xu, Jianlin
Zhong, Hua
Xia, Jinjing
Zhong, Runbo
CANCER SCIENCE, 2024,
[48] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
Yang, Zhengquan
Li, Jialu
Hu, Yujie
Chen, Meihua
Peng, Danli
Zong, Dan
Shang, Qingjuan
Tao, Lianqin
Zhao, Yanling
Ni, Yiyun
Ye, Jinyan
Xie, Yupeng
Yang, Li
Lin, Quan
Cai, Chang
Xu, Ning
Huang, Xiaoping
Dong, Xiaoting
Zhou, Zhonghui
Yu, Yali
Shangguan, Zongxiao
Xu, Yangyang
Ying, Weiping
Weng, Meiling
Yuan, Zuguo
Dong, Zhijun
Li, Jifa
Zheng, Zhe
Pan, Jiongwei
Liu, Lu
Ye, Junhui
Zhang, Zhan
Li, Wenfeng
Zhu, Junfei
Jin, Shengnan
Li, Yuping
Ding, Chunming
TARGETED ONCOLOGY, 2019, 14 (06) : 719 - 728
[49] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
Zhengquan Yang
Jialu Li
Yujie Hu
Meihua Chen
Danli Peng
Dan Zong
Qingjuan Shang
Lianqin Tao
Yanling Zhao
Yiyun Ni
Jinyan Ye
Yupeng Xie
Li Yang
Quan Lin
Chang Cai
Ning Xu
Xiaoping Huang
Xiaoting Dong
Zhonghui Zhou
Yali Yu
Zongxiao Shangguan
Yangyang Xu
Weiping Ying
Meiling Weng
Zuguo Yuan
Zhijun Dong
Jifa Li
Zhe Zheng
Jiongwei Pan
Lu Liu
Junhui Ye
Zhan Zhang
Wenfeng Li
Junfei Zhu
Shengnan Jin
Yuping Li
Chunming Ding
Targeted Oncology, 2019, 14 : 719 - 728
[50] Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Chih-Hsi Scott Kuo
Chi-Hsien Huang
Chien-Ying Liu
Stelios Pavlidis
Ho-Wen Ko
Fu-Tsai Chung
Tin-Yu Lin
Chih-Liang Wang
Yi-Ke Guo
Cheng-Ta Yang
Targeted Oncology, 2019, 14 : 433 - 440

← 1 2 3 4 5 →